Douglas Lane & Associates LLC lessened its holdings in shares of Celgene Co. (NASDAQ:CELG) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 385,890 shares of the biopharmaceutical company’s stock after selling 9,832 shares during the period. Douglas Lane & Associates LLC’s holdings in Celgene were worth $56,270,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of CELG. Thompson Davis & CO. Inc. grew its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI grew its position in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares during the period. Motco grew its position in shares of Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 159 shares during the period. Penserra Capital Management LLC acquired a new stake in shares of Celgene during the 2nd quarter valued at about $129,000. Finally, Balentine LLC grew its position in shares of Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 481 shares during the period. Hedge funds and other institutional investors own 79.74% of the company’s stock.
Several research firms recently issued reports on CELG. Vetr upgraded Celgene from a “hold” rating to a “buy” rating and set a $146.58 price objective on the stock in a report on Friday, October 6th. Royal Bank of Canada reiterated a “buy” rating and issued a $173.00 price objective on shares of Celgene in a report on Thursday, October 5th. Cantor Fitzgerald reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Tuesday, September 26th. Robert W. Baird reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene in a report on Thursday, September 21st. Finally, Jefferies Group reissued a “buy” rating and issued a $160.00 target price on shares of Celgene in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the stock. Celgene currently has an average rating of “Buy” and an average price target of $131.18.
Shares of Celgene Co. (CELG) traded up $1.42 during mid-day trading on Friday, hitting $106.00. 8,750,000 shares of the company were exchanged, compared to its average volume of 6,330,000. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $83,460.00, a P/E ratio of 25.00, a P/E/G ratio of 0.68 and a beta of 1.77. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.58 earnings per share. equities analysts expect that Celgene Co. will post 6.68 earnings per share for the current fiscal year.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.